Biomarkers for diagnosis, monitoring of progression, and treatment responses in ankylosing spondylitis and axial spondyloarthritis

Clinical Rheumatology

Volumn 34, Issue 6, 2015, Pages 1009-1018

  Reveille, John D ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

Biomarkers; Diagnostic tools; Genetics; Radiographic outcome; Spondyloarthritis; Treatment response

Indexed keywords

ADIPOCYTOKINE; AGGRECAN; BIOLOGICAL MARKER; C REACTIVE PROTEIN; CALGRANULIN; CARTILAGE OLIGOMERIC MATRIX PROTEIN; EOMESODERMIN; FETUIN A; GELATINASE B; GLYCOPROTEIN GP 39; HLA B ANTIGEN; HLA B27 ANTIGEN; HLA B40 ANTIGEN; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 1; INTERLEUKIN 17; INTERLEUKIN 23; INTERLEUKIN 23 RECEPTOR; INTERLEUKIN 33; INTERLEUKIN 6; INTERLEUKIN 6 RECEPTOR; MATRIX METALLOPROTEINASE 16; NEUTROPHIL COLLAGENASE; PROTEIN KINASE TYK2; SCLEROSTIN; SERUM AMYLOID A; STROMELYSIN; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TRANSCRIPTION FACTOR RUNX3; VASCULOTROPIN; CHI3L1 PROTEIN, HUMAN; CHITINASE 3 LIKE PROTEIN 1; CYTOKINE; GENETIC MARKER; LECTIN; MATRIX METALLOPROTEINASE; OSTEOPROTEGERIN;

ANKYLOSING SPONDYLITIS; ARTICLE; AXIAL SPONDYLOARTHRITIS; BONE METABOLISM; CARTILAGE; CLINICAL TRIAL (TOPIC); CONNECTIVE TISSUE; CYTOKINE PRODUCTION; DISEASE ACTIVITY; DISEASE CLASSIFICATION; DISEASE COURSE; DISEASE MARKER; DISEASE PREDISPOSITION; ERYTHROCYTE SEDIMENTATION RATE; GENETIC ASSOCIATION; GENETIC MARKER; HEREDITY; HUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN DEGRADATION; SPONDYLARTHRITIS; TREATMENT RESPONSE; BONE; GENETICS; METABOLISM; SPONDYLARTHROPATHIES; SPONDYLITIS, ANKYLOSING; TREATMENT OUTCOME;

ADIPOKINES; AGGRECANS; BIOMARKERS; BONE AND BONES; CARTILAGE; CARTILAGE OLIGOMERIC MATRIX PROTEIN; CHITINASE-3-LIKE PROTEIN 1; CONNECTIVE TISSUE; CYTOKINES; DISEASE PROGRESSION; GENETIC MARKERS; HLA-B27 ANTIGEN; HUMANS; LECTINS; LEUKOCYTE L1 ANTIGEN COMPLEX; MATRIX METALLOPROTEINASES; OSTEOPROTEGERIN; SPONDYLARTHROPATHIES; SPONDYLITIS, ANKYLOSING; TREATMENT OUTCOME;

EID: 84929962351     PISSN: 07703198     EISSN: 14349949     Source Type: Journal    
DOI: 10.1007/s10067-015-2949-3     Document Type: Article

References (75)

1. Weisman MH, Witter JP, Reveille JD (2013) The prevalence of inflammatory back pain: population-based estimates from the US National Health and Nutrition Examination Survey, 2009–10. Ann Rheum Dis 72(3):369–373
2. Rudwaleit M, Metter A, Listing J, Sieper J, Braun J (2006) Inflammatory back pain in ankylosing spondylitis: a reassessment of the clinical history for application as classification and diagnostic criteria. Arthritis Rheum 54(2):569–578
3. Reveille JD, Witter JP, Weisman MH (2012) Prevalence of axial spondyloarthritis in the United States: estimates from a cross-sectional survey. Arthritis Care Res (Hoboken) 64(6):905–910
4. Garrett S, Jenkinson T, Kennedy LG, Whitelock H, Gaisford P, Calin A (1994) A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol 21(12):2286–2291
5. Van der Heijde D, Lie E, Kvien TK, Sieper J, Van den Bosch F, Listing J, Braun J, Landewé R (2009) ASDAS, a highly discriminatory ASAS-endorsed disease activity score in patients with ankylosing spondylitis. Ann Rheum Dis 68(12):1811–1818
6. Calin A, Garrett S, Whitelock H, Kennedy LG, O'Hea J, Mallorie P, Jenkinson T (1994) A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index. J Rheumatol 21(12):2281–2285
7. van der Heijde D, Landewé R (2005) Selection of a method for scoring radiographs for ankylosing spondylitis clinical trials, by the Assessment in Ankylosing Spondylitis Working Group and OMERACT. J Rheumatol 32(10):2048–2049
8. van der Linden S, Valkenburg HA, Cats A (1984) Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum 27(4):361–368
9. Rudwaleit M, Khan MA, Sieper J (2005) The challenge of diagnosis and classification in early ankylosing spondylitis: do we need new criteria? Arthritis Rheum 52(4):1000–1008
10. Rudwaleit M, Landewe R, van der Heijde D, Listing J, Brandt J, Braun J et al (2009) The development of Assessment of SpondyloArthritis International Society classification criteria for axial spondyloarthritis (part I): classification of paper patients by expert opinion including uncertainty appraisal. Ann Rheum Dis 68(6):770–776
11. Haroon N, Inman RD, Learch TJ, Weisman MH, Lee M, Rahbar MH et al (2013) The impact of TNF-inhibitors on radiographic progression in Ankylosing Spondylitis. Arthritis Rheum 65(10):2645–2654
12. Reveille JD, Hirsch R, Dillon CF, Carroll MD, Weisman MH (2012) The prevalence of HLA-B27 in the US: data from the US National Health and Nutrition Examination Survey, 2009. Arthritis Rheum 64(5):1407–1411
13. Bennett AN, McGonagle D, O'Connor P, Hensor EM, Sivera F, Coates LC et al (2008) Severity of baseline magnetic resonance imaging-evident sacroiliitis and HLA-B27 status in early inflammatory back pain predict radiographically evident ankylosing spondylitis at eight years. Arthritis Rheum 58(11):3413–3418
14. Sieper J, Srinivasan S, Zamani O, Mielants H, Choquette D, Pavelka K et al (2013) Comparison of two referral strategies for diagnosis of axial spondyloarthritis: the Recognising and Diagnosing Ankylosing Spondylitis Reliably (RADAR) study. Ann Rheum Dis 72(10):1621–1627
15. Cortes A, Hadler J, Pointon JP, Robinson PC, Karaderi T, Leo P et al (2013) Identification of multiple risk variants for ankylosing spondylitis through high-density genotyping of immune-related loci. Nat Genet 45(7):730–738
16. Annas GJ, Elias S (2014) 23andMe and the FDA. N Engl J Med 370:985–988
17. Robinson PC, Claushuis TA, Cortes A, Martin TM, Evans DM, Leo P et al (2015) Genetic dissection of acute anterior uveitis reveals similarities and differences in associations observed with ankylosing spondylitis. Arthritis Rheumatol 67(1):140–151
18. Cortes A, Maksymowych WP, Wordsworth BP, Inman RD, Danoy P, Rahman P et al (2014) Association study of genes related to bone formation and resorption and the extent of radiographic change in ankylosing spondylitis. Ann Rheum Dis. doi:10.1136/annrheumdis-2013-204835, Epub ahead of print
19. Spoorenberg A, van der Heijde D, de Klerk E, Dougados M, de Vlam K, Mielants H, van der Tempel H, van der Linden S (1999) Relative value of erythrocyte sedimentation rate and C-reactive protein in assessment of disease activity in ankylosing spondylitis. J Rheumatol 26(4):980–984
20. Ruof J, Stucki G (1999) Validity aspects of erythrocyte sedimentation rate and C-reactive protein in ankylosing spondylitis: a literature review. J Rheumatol 26(4):966–970
21. Rudwaleit M, Haibel H, Baraliakos X, Listing J, Marker-Hermann E, Zeidler H et al (2009) The early disease stage in axial spondylarthritis: results from the German Spondyloarthritis Inception Cohort. Arthritis Rheum 60(3):717–727
22. Wallis D, Haroon N, Ayearst R, Carty A, Inman RD (2013) Ankylosing spondylitis and nonradiographic axial spondyloarthritis: part of a common spectrum or distinct diseases? J Rheumatol 40(12):2038–2041
23. Bredella MA, Steinbach LS, Morgan S, Ward M, Davis JC (2006) MRI of the sacroiliac joints in patients with moderate to severe ankylosing spondylitis. AJR Am J Roentgenol 187(6):1420–1426
24. Poddubnyy DA, Rudwaleit M, Listing J, Braun J, Sieper J (2010) Comparison of a high sensitivity and standard C reactive protein measurement in patients with ankylosing spondylitis and non-radiographic axial spondyloarthritis. Ann Rheum Dis 69(7):1338–1341
25. Gratacós J, Collado A, Filella X, Sanmartí R, Cañete J, Llena J, Molina R, Ballesta A, Muñoz-Gómez J (1994) Serum cytokines (IL-6, TNF-alpha, IL-1 beta and IFN-gamma) in ankylosing spondylitis: a close correlation between serum IL-6 and disease activity and severity. Br J Rheumatol 33(10):927–931
26. Bal A, Unlu E, Bahar G, Aydog E, Eksioglu E, Yorgancioglu R (2007) Comparison of serum IL-1 beta, sIL-2R, IL-6, and TNF-alpha levels with disease activity parameters in ankylosing spondylitis. Clin Rheumatol 26(2):211–215
27. Romero-Sanchez C, Jaimes DA, Londoño J, De Avila J, Castellanos JE, Bello JM, Bautista W, Valle-Oñate R (2011) Association between Th-17 cytokine profile and clinical features in patients with spondyloarthritis. Clin Exp Rheumatol 29(5):828–834
28. Pedersen SJ, Sørensen IJ, Garnero P, Johansen JS, Madsen OR, Tvede N et al (2011) ASDAS, BASDAI and different treatment responses and their relation to biomarkers of inflammation, cartilage and bone turnover in patients with axial spondyloarthritis treated with TNFα inhibitors. Ann Rheum Dis 70(8):1375–1381
29. Sveaas SH, Berg IJ, Provan SA, Semb AG, Olsen IC, Ueland T et al (2015) Circulating levels of inflammatory cytokines and cytokine receptors in patients with ankylosing spondylitis: a cross-sectional comparative study. Scand J Rheumatol 44(2):118–124
30. Mei Y, Pan F, Gao J, Ge R, Duan Z, Zeng Z et al (2011) Increased serum IL-17 and IL-23 in the patient with ankylosing spondylitis. Clin Rheumatol 30(2):269–273
31. Chen WS, Chang YS, Lin KC, Lai CC, Wang SH, Hsiao KH et al (2012) Association of serum interleukin-17 and interleukin-23 levels with disease activity in Chinese patients with ankylosing spondylitis. J Chin Med Assoc 75(7):303–308
32. Andersen T, Rasmussen TK, Hvid M, Holm CK, Madsen KJ, Jurik AG et al (2012) Increased plasma levels of IL-21 and IL-23 in spondyloarthritis are not associated with clinical and MRI findings. Rheumatol Int 32(2):387–393
33. Li XL, Lin TT, Qi CY, Yuan L, Xia LP, Shen H, Lu J (2013) Elevated serum level of IL-33 and sST2 in patients with ankylosing spondylitis: associated with disease activity and vascular endothelial growth factor. J Investig Med 61(5):848–851
34. Li GX, Wang S, Duan ZH, Zeng Z, Pan FM (2013) Serum levels of IL-33 and its receptor ST2 are elevated in patients with ankylosing spondylitis. Scand J Rheumatol 42(3):226–231
35. Han GW, Zeng LW, Liang CX, Cheng BL, Yu BS, Li HM, Zeng FF, Liu SY (2011) Serum levels of IL-33 is increased in patients with ankylosing spondylitis. Clin Rheumatol 30(12):1583–1588
36. Keyszer G, Lambiri I, Nagel R, Keysser C, Keysser M, Gromnica-Ihle E et al (1999) Circulating levels of matrix metalloproteinases MMP-3 and MMP-1, tissue inhibitor of metalloproteinases 1 (TIMP-1), and MMP-1/TIMP-1 complex in rheumatic disease. Correlation with clinical activity of rheumatoid arthritis versus other surrogate markers. J Rheumatol 26(2):251–258
37. Chen CH, Lin KC, Yu DT, Yang C, Huang F, Chen HA et al (2006) Serum matrix metalloproteinases and tissue inhibitors of metalloproteinases in ankylosing spondylitis: MMP-3 is a reproducibly sensitive and specific biomarker of disease activity. Rheumatology (Oxford) 45(4):414–420
38. Mattey DL, Packham JC, Nixon NB, Coates L, Creamer P, Hailwood S, Taylor GJ, Bhalla AK (2012) Association of cytokine and matrix metalloproteinase profiles with disease activity and function in ankylosing spondylitis. Arthritis Res Ther 28;14(3):R127
39. Yang C, Gu J, Rihl M, Baeten D, Huang F, Zhao M et al (2004) Serum levels of matrix metalloproteinase 3 and macrophage colony-stimulating factor 1 correlate with disease activity in ankylosing spondylitis. Arthritis Rheum 51(5):691–699
40. Wendling D, Cedoz JP, Racadot E (2008) Serum levels of MMP-3 and cathepsin K in patients with ankylosing spondylitis: effect of TNF alpha antagonist therapy. Joint Bone Spine 75(5):559–562
41. Sun S, Bay-Jensen AC, Karsdal MA, Siebuhr AS, Zheng Q, Maksymowych WP, Christiansen TG, Henriksen K (2014) The active form of MMP-3 is a marker of synovial inflammation and cartilage turnover in inflammatory joint diseases. BMC Musculoskelet Disord 19(15):93. doi:10.1186/1471-2474-15-93
42. Woo JH, Lee HJ, Sung IH, Kim TH (2007) Changes of clinical response and bone biochemical markers in patients with ankylosing spondylitis taking etanercept. J Rheumatol 34(8):1753–1759
43. Arends S, van der Veer E, Groen H, Houtman PM, Jansen TL, Leijsma MK et al (2011) Serum MMP-3 level as a biomarker for monitoring and predicting response to etanercept treatment in ankylosing spondylitis. J Rheumatol 38(8):1644–1650
44. Turina MC, Yeremenko N, Paramarta JE, De Rycke L, Baeten D (2014) Calprotectin (S100A8/9) as serum biomarker for clinical response in proof-of-concept trials in axial and peripheral spondyloarthritis. Arthritis Res Ther 16(4):413. doi:10.1186/s13075-014-0413-4
45. Maksymowych WP, Landewé R, Conner-Spady B, Dougados M, Mielants H, van der Tempel H, Poole AR, Wang N, van der Heijde D (2007) Serum matrix metalloproteinase 3 is an independent predictor of structural damage progression in patients with ankylosing spondylitis. Arthritis Rheum 56(6):1846–1853
46. Taylan A, Sari I, Akinci B, Bilge S, Kozaci D, Akar S et al (2012) Biomarkers and cytokines of bone turnover: extensive evaluation in a cohort of patients with ankylosing spondylitis. BMC Musculoskelet Disord 13:191. doi:10.1186/1471-2474-13-191
47. Franck H, Meurer T, Hofbauer LC (2004) Evaluation of bone mineral density, hormones, biochemical markers of bone metabolism, and osteoprotegerin serum levels in patients with ankylosing spondylitis. J Rheumatol 31(11):2236–2241
48. Genre F, López-Mejías R, Miranda-Filloy JA, Ubilla B, Carnero-López B, Palmou-Fontana N et al (2014) Osteoprotegerin correlates with disease activity and endothelial activation in non-diabetic ankylosing spondylitis patients undergoing TNF-α antagonist therapy. Clin Exp Rheumatol 32(5):640–646
49. Chen CH, Chen HA, Liao HT, Liu CH, Tsai CY, Chou CT (2010) Soluble receptor activator of nuclear factor-kappaB ligand (RANKL) and osteoprotegerin in ankylosing spondylitis: OPG is associated with poor physical mobility and reflects systemic inflammation. Clin Rheumatol 29(10):1155–1161
50. Klingberg E, Nurkkala M, Carlsten H, Forsblad-d'Elia H (2014) Biomarkers of bone metabolism in ankylosing spondylitis in relation to osteoproliferation and osteoporosis. J Rheumatol 41(7):1349–1356
51. de Andrade KR, de Castro GR, Vicente G, da Rosa JS, Nader M, Pereira IA, Fröde TS (2014) Evaluation of circulating levels of inflammatory and bone formation markers in axial spondyloarthritis. Int Immunopharmacol 21(2):481–486
52. Matzkies FG, Targan SR, Berel D, Landers CJ, Reveille JD, McGovern DP, Weisman MH (2012) Markers of intestinal inflammation in patients with ankylosing spondylitis: a pilot study. Arthritis Res Ther 14(6):R261. doi:10.1186/ar4106
53. Schonthaler HB, Guinea-Viniegra J, Wculek SK, Ruppen I, Ximenez-Embun P, Guio-Carrion A, Navarro R, Hogg N, Ashman K, Wagner EF (2013) S100A8-S100A9 protein complex mediates psoriasis by regulating the expression of complement factor C3. Immunity 39:1171–1181
54. Hammer HB, Kvien TK, Glennås A, Melby K (1995) A longitudinal study of calprotectin as an inflammatory marker in patients with reactive arthritis. Clin Exp Rheumatol 13(1):59–64
55. Turina MC, Sieper J, Yeremenko N, Conrad K, Haibel H, Rudwaleit M, Baeten D, Poddubnyy D (2014) Calprotectin serum level is an independent marker for radiographic spinal progression in axial spondyloarthritis. Ann Rheum Dis 73(9):1746–1748
56. Drouart M, Saas P, Billot M, Cedoz JP, Tiberghien P, Wendling D, Toussirot E (2003) High serum vascular endothelial growth factor correlates with disease activity of spondylarthropathies. Clin Exp Immunol 132(1):158–162
57. Poddubnyy D, Conrad K, Haibel H, Syrbe U, Appel H, Braun J, Rudwaleit M, Sieper J (2014) Elevated serum level of the vascular endothelial growth factor predicts radiographic spinal progression in patients with axial spondyloarthritis. Ann Rheum Dis 73(12):2137–2143
58. Vosse D, Landewé R, Garnero P, van der Heijde D, van der Linden S, Geusens P (2008) Association of markers of bone- and cartilage-degradation with radiological changes at baseline and after 2 years follow-up in patients with ankylosing spondylitis. Rheumatology (Oxford) 47(8):1219–1222
59. Arends S, Spoorenberg A, Efde M, Bos R, Leijsma MK, Bootsma H et al (2014) Higher bone turnover is related to spinal radiographic damage and low bone mineral density in ankylosing spondylitis patients with active disease: a cross-sectional analysis. PLoS ONE 11;9(6):e99685. doi:10.1371/journal.pone.0099685
60. Bay-Jensen AC, Karsdal MA, Vassiliadis E, Wichuk S, Marcher-Mikkelsen K, Lories R, Christiansen C, Maksymowych WP (2013) Circulating citrullinated vimentin fragments reflect disease burden in ankylosing spondylitis and have prognostic capacity for radiographic progression. Arthritis Rheum 65(4):972–980
61. Pedersen SJ, Sørensen IJ, Lambert RG, Hermann KG, Garnero P, Johansen JS et al (2011) Radiographic progression is associated with resolution of systemic inflammation in patients with axial spondylarthritis treated with tumor necrosis factor α inhibitors: a study of radiographic progression, inflammation on magnetic resonance imaging, and circulating biomarkers of inflammation, angiogenesis, and cartilage and bone turnover. Arthritis Rheum 63(12):3789–3800
62. Bay-Jensen AC, Wichuk S, Byrjalsen I, Leeming DJ, Morency N, Christiansen C, Karsdal MA, Maksymowych WP (2013) Circulating protein fragments of cartilage and connective tissue degradation are diagnostic and prognostic markers of rheumatoid arthritis and ankylosing spondylitis. PLoS ONE 8(1):e54504. doi:10.1371/journal.pone.0054504
63. Appel H, Ruiz-Heiland G, Listing J, Zwerina J, Herrmann M, Mueller R et al (2009) Altered skeletal expression of sclerostin and its link to radiographic progression in ankylosing spondylitis. Arthritis Rheum 60(11):3257–3262
64. Saad CG, Ribeiro AC, Moraes JC, Takayama L, Goncalves CR, Rodrigues MB et al (2012) Low sclerostin levels: a predictive marker of persistent inflammation in ankylosing spondylitis during anti-tumor necrosis factor therapy? Arthritis Res Ther 14(5):R216. doi:10.1186/ar4055
65. Tuylu T, Sari I, Solmaz D, Kozaci DL, Akar S, Gunay N, Onen F, Akkoc N (2014) Fetuin-A is related to syndesmophytes in patients with ankylosing spondylitis: a case control study. Clinics (Sao Paulo) 69(10):688–693
66. Korkosz M, Gąsowski J, Leszczyński P, Pawlak-Buś K, Jeka S, Kucharska E, Grodzicki T (2013) High disease activity in ankylosing spondylitis is associated with increased serum sclerostin level and decreased wingless protein-3a signaling but is not linked with greater structural damage. BMC Musculoskelet Disord 14:99. doi:10.1186/1471-2474-14-99
67. Heiland GR, Appel H, Poddubnyy D, Zwerina J, Hueber A, Haibel H et al (2012) High level of functional dickkopf-1 predicts protection from syndesmophyte formation in patients with ankylosing spondylitis. Ann Rheum Dis 71(4):572–574
68. Yucong Z, Lu L, Shengfa L, Yongliang Y, Ruguo S, Yikai L (2014) Serum functional dickkopf-1 levels are inversely correlated with radiographic severity of ankylosing spondylitis. Clin Lab 60(9):1527–1531
69. Kwon SR, Lim MJ, Suh CH, Park SG, Hong YS, Yoon BY et al (2012) Dickkopf-1 level is lower in patients with ankylosing spondylitis than in healthy people and is not influenced by anti-tumor necrosis factor therapy. Rheumatol Int 32(8):2523–2527
70. Franck H, Keck E (1993) Serum osteocalcin and vitamin D metabolites in patients with ankylosing spondylitis. Ann Rheum Dis 52(5):343–346
71. Yilmaz N, Ozaslan J (2000) Biochemical bone turnover markers in patients with ankylosing spondylitis. Clin Rheumatol 19(2):92–98
72. Visvanathan S, van der Heijde D, Deodhar A, Wagner C, Baker DG, Han J et al (2009) Effects of infliximab on markers of inflammation and bone turnover and associations with bone mineral density in patients with ankylosing spondylitis. Ann Rheum Dis 68:175–182
73. Genre F, López-Mejías R, Miranda-Filloy JA, Ubilla B, Carnero-López B, Blanco R, Pina T, González-Juanatey C, Llorca J, González-Gay MA (2014) Adipokines, biomarkers of endothelial activation, and metabolic syndrome in patients with ankylosing spondylitis.Biomed Res Int.;2014:860651. doi: 10.1155/2014/860651
74. Kim KJ, Kim JY, Park SJ, Yoon H, Yoon CH, Kim WU, Cho CS (2012) Serum leptin levels are associated with the presence of syndesmophytes in male patients with ankylosing spondylitis. Clin Rheumatol 31(8):1231–1238
75. Syrbe U, Callhoff J, Conrad K, Poddubnyy D, Haibel H, Junker S et al (2015) Serum adipokine levels in patients with ankylosing spondylitis and their relationship to clinical parameters and radiographic spinal progression. Arthritis Rheumatol 67(3):678–685